Skip to main content

eFFECTOR Therapeutics, Inc. (EFTR)

NASDAQ: EFTR · IEX Real-Time Price · USD
19.32
+0.02 (0.10%)
After-hours:Sep 17, 2021 7:57 PM EDT
19.30
-0.28 (-1.43%)
At close: Sep 17, 4:00 PM
Market Cap772.72M
Revenue (ttm)1.31M
Net Income (ttm)n/a
Shares Out40.67M
EPS (ttm)-0.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume480,961
Open19.69
Previous Close19.58
Day's Range18.20 - 20.38
52-Week Range8.52 - 40.42
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About EFTR

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to tre...

IndustryBiotechnology
Founded2012
Stock ExchangeNASDAQ
Ticker SymbolEFTR
Full Company Profile

Financial Performance

Financial Statements

News

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today a...

2 days ago - GlobeNewsWire

What's Going On With eFFECTOR Therapeutics Stock Today?

eFFECTOR Therapeutics Inc (NASDAQ: EFTR) is trading higher Monday after Cantor Fitzgerald initiated coverage on the stock. Cantor Fitzgerald analyst Louise Chen initiated coverage on eFFECTOR Therapeuti...

5 days ago - Benzinga

Why eFFECTOR Therapeutics Stock Is Heating Up Today

The biotech's novel cancer platform is fueling buyout speculation on social media today.

1 week ago - The Motley Fool

ARQQ Stock: What Is Going on With Red-Hot Arqit Quantum Today?

Since its debut yesterday, ARQQ stock has made significant gains. What does this say about the future and power of SPACs?

Other symbols:ARQQHIPOLCID
1 week ago - InvestorPlace

EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%

Here's what investors may want to know about eFFECTOR and EFTR stock, as the company's shares surge once again today in a big way. The post EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up...

1 week ago - InvestorPlace

EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?

After a tough week for SPACs, EFTR stock has enjoyed significant gains today. The SPAC bubble may not be over yet.

1 week ago - InvestorPlace

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New C...

Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW Common stock and warrants expected to commence trading on Nasdaq on August 26,...

3 weeks ago - GlobeNewsWire

LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing

Locust Walk Acquisition (LWAC) stock is rocketing higher on Wednesday following news that it can move forward with the eFFECTOR Therapeutics. The post LWAC Stock: eFFECTOR Therapeutics SPAC Merger News ...

3 weeks ago - InvestorPlace

Why Is This SPAC Surging 160% Today?

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective transla...

3 weeks ago - Benzinga

Moore Kuehn Encourages FMBI, LWAC, LEGO and FORE Investors to Contact Law Firm

NEW YORK, June 21, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whe...

Other symbols:FMBIFORELEGO
2 months ago - PRNewsWire

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Gen...

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors (STRI...

3 months ago - GlobeNewsWire

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal.  The SPAC Deal: eFFECTOR Therapeutics will merge with Locust Walk Acquisition Co...

3 months ago - Benzinga

Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1, 2021

PHILADELPHIA and BOSTON, Feb. 22, 2021 /PRNewswire/ -- Locust Walk Acquisition Corp. (NASDAQ: LWACU) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or mor...

6 months ago - PRNewsWire

Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Ove...

PHILADELPHIA and BOSTON, Jan. 12, 2021 /PRNewswire/ -- Locust Walk Acquisition Corp. (NASDAQ: LWACU) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or mor...

8 months ago - PRNewsWire

Locust Walk Acquisition Corp. Announces Pricing of Upsized $153,000,000 Initial Public Offering

PHILADELPHIA and BOSTON, Jan. 7, 2021 /PRNewswire/ -- Locust Walk Acquisition Corp. (NASDAQ:LWACU) (the "Company"), a blank check company formed for the purpose of acquiring or merging with one or more ...

8 months ago - PRNewsWire

Locust Walk Acquisition IPO Registration Document (S-1)

Locust Walk Acquisition Corp. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC